We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunohistochemistry Evaluated for Tissue-Invasive Cytomegalovirus in Gastrointestinal Mucosal Biopsies

By LabMedica International staff writers
Posted on 04 Mar 2022
Image: Photomicrograph of cytomegalovirus colitis (Photo courtesy of Nephron)
Image: Photomicrograph of cytomegalovirus colitis (Photo courtesy of Nephron)

Cytomegalovirus (CMV) immunohistochemistry (IHC) is the most widely used method to diagnose CMV infection/reactivation in tissues in a pathology laboratory.

Cytomegalovirus (CMV), an encapsulated double-stranded DNA β-herpesvirus, often causes asymptomatic or mild mononucleosis-like primary infection followed by latent infection or chronic infection. About 40% to 100% of the world's adult population is seropositive for CMV.

Gastrointestinal (GI) CMV disease can manifest during primary infection or reactivation of latent virus. Reactivation of CMV is frequently seen in adults, especially in patients with immunocompromised conditions such as human immunodeficiency virus (HIV) infection, recipients of solid organ and stem cell transplant, and those with disease treated by immunosuppressive medications.

A team of pathologists at the New York University Langone Health (New York, NY, USA) included in a study total of 1,479 mucosal biopsies from the GI system. Their aim was to improve the efficiency of CMV immunohistochemistry (IHC) testing by evaluating immunopositive staining trends of tissue-invasive CMV in the gastrointestinal system. Immunohistochemistry was performed with specific antibodies against CMV (DAKO, Santa Clara, CA, USA).

The investigators reported that the overall positivity rate of CMV IHC was 4.73% (70/1,479). The positivity rate from physician-requested and pathologist-initiated tests was significantly different (7.54% versus 3.83%). Cases with severe inflammation showed a higher positive CMV rate than those with mild inflammation (5.37% versus 2.6%). Cytomegalovirus positivity in biopsies from post-transplant patients, inflammatory bowel disease, human immunodeficiency virus (HIV)/common variable immunodeficiency (CVID), cancer, and others was 19.69%, 3.84%, 23.33%, 9.0%, and 2.84%, respectively.

The positivity rate among post-transplant, HIV/CVID, or cancer patients was significantly higher than in other populations. Cases tested with multiple tissue blocks generated a higher positivity rate than those with a single block (7.77% versus 3.23%). Testing three to four blocks per case almost tripled the positive CMV detection rate (9.04%). Interestingly, using five or more blocks did not further ameliorate the positive CMV detection rate.

The authors concluded that physician request, immunosuppression, multiple blocks, and severe inflammation were strongly related to positive CMV IHC detection rate. These findings might provide value in helping pathologists manage CMV IHC testing more efficiently. The study published in the March 2022 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
New York University Langone Health 
DAKO 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Neonatal Heel Incision Device
Tenderfoot

Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more